• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    4/4/24 12:31:14 PM ET
    $ACHL
    $BRNS
    $CADL
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACHL alert in real time by email

    Gainers

    • Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 61.38% to $2.1. The market value of their outstanding shares is at $5.0 million.
    • Eiger BioPharmaceuticals (NASDAQ:EIGR) shares moved upwards by 38.18% to $2.28. The company's market cap stands at $3.3 million.
    • Macrogenics (NASDAQ:MGNX) stock rose 32.55% to $18.12. The company's market cap stands at $1.1 billion.
    • Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 29.55% to $3.77. The company's market cap stands at $146.7 million.
    • Curis (NASDAQ:CRIS) shares moved upwards by 24.62% to $16.7. The market value of their outstanding shares is at $98.4 million.

    Losers

    • eFFECTOR Therapeutics (NASDAQ:EFTR) stock declined by 80.2% to $3.25 during Thursday's regular session. The company's market cap stands at $11.9 million.
    • Achilles Therapeutics (NASDAQ:ACHL) stock decreased by 24.17% to $0.91. The market value of their outstanding shares is at $37.1 million. As per the press release, Q4 earnings came out today.
    • Inotiv (NASDAQ:NOTV) shares fell 16.81% to $7.87. The company's market cap stands at $202.9 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) stock declined by 14.55% to $2.35. The company's market cap stands at $8.5 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares declined by 13.48% to $0.14. The market value of their outstanding shares is at $5.5 million.
    • Carmell (NASDAQ:CTCX) stock declined by 12.85% to $2.51. The market value of their outstanding shares is at $48.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHL
    $BRNS
    $CADL
    $CRIS

    CompanyDatePrice TargetRatingAnalyst
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    MacroGenics Inc.
    $MGNX
    9/17/2025$3.00Overweight
    Barclays
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    Candel Therapeutics Inc.
    $CADL
    6/30/2025$23.00Buy
    H.C. Wainwright
    Curis Inc.
    $CRIS
    5/19/2025$17.00Buy
    H.C. Wainwright
    Candel Therapeutics Inc.
    $CADL
    2/20/2025$25.00Buy
    Citigroup
    Candel Therapeutics Inc.
    $CADL
    2/19/2025$20.00Buy
    Canaccord Genuity
    Candel Therapeutics Inc.
    $CADL
    2/7/2025$15.00Buy
    BofA Securities
    More analyst ratings

    $ACHL
    $BRNS
    $CADL
    $CRIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Candel Therapeutics with a new price target

    Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00

    10/28/25 8:02:46 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays resumed coverage on MacroGenics with a new price target

    Barclays resumed coverage of MacroGenics with a rating of Overweight and set a new price target of $3.00

    9/17/25 8:02:48 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Candel Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Candel Therapeutics from Buy to Neutral and set a new price target of $7.00

    9/3/25 8:04:26 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    $BRNS
    $CADL
    $CRIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Taylor Beth A. sold $846 worth of shares (2,888 units at $0.29), decreasing direct ownership by 2% to 145,480 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    2/19/26 4:41:21 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Strategy Officer Sagartz John E sold $616 worth of shares (2,119 units at $0.29), decreasing direct ownership by 0.29% to 735,697 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    2/19/26 4:40:25 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ACHL
    $BRNS
    $CADL
    $CRIS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

    Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030, a first-in-class TOP1i-based ADC, on track for 3Q 2026Cash, cash equivalents and marketable securities of $189.9 million as of December 31, 2025; cash runway guidance remains into late 2027 ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for th

    3/9/26 4:01:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

    NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session, as part of the American Urological Association (AUA) 2026 Annual Meeting Plenary Program being held in Washington D.C. from May 15-18, 2026. The presentation will feature new data from the Company's phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with interm

    3/9/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on February 28, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 20,000 shares of the Company's common stock, with a per share exercise price of $5.25. The inducement stock options were made under the Company's 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award

    3/2/26 4:05:00 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    $BRNS
    $CADL
    $CRIS
    SEC Filings

    View All

    Inotiv Inc. filed SEC Form 8-K: Other Events

    8-K - Inotiv, Inc. (0000720154) (Filer)

    3/10/26 8:13:31 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MACROGENICS INC (0001125345) (Filer)

    3/9/26 4:12:10 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by MacroGenics Inc.

    10-K - MACROGENICS INC (0001125345) (Filer)

    3/9/26 4:10:34 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHL
    $BRNS
    $CADL
    $CRIS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Heiden William K bought $150,515 worth of shares (100,000 units at $1.51), increasing direct ownership by 909% to 111,000 units (SEC Form 4)

    4 - MACROGENICS INC (0001125345) (Issuer)

    8/21/25 4:19:48 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Landman David bought $99,998 worth of shares (23,529 units at $4.25), increasing direct ownership by 15% to 176,851 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/23/24 9:47:13 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ACHL
    $BRNS
    $CADL
    $CRIS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MARGENZA issued to MACROGENICS INC

    Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

    5/29/23 4:45:45 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MARGENZA

    Submission status for MACROGENICS INC's drug MARGENZA (ORIG-1) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 12/16/2020. Application Category: BLA, Application Number: 761150, Application Classification:

    12/20/20 4:31:01 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHL
    $BRNS
    $CADL
    $CRIS
    Leadership Updates

    Live Leadership Updates

    View All

    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

    NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311

    10/16/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

    NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel's Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 f

    9/2/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MacroGenics Appoints Eric Risser as President and Chief Executive Officer

    ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company's corporate development efforts, which have generated over $1.6 billion in non-dilutive capital since inception. Mr. Risser succeeds Scott Koenig, M.D., Ph.D. who is stepping down after serving as Presi

    8/13/25 4:01:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHL
    $BRNS
    $CADL
    $CRIS
    Financials

    Live finance-specific insights

    View All

    Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

    –   First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million –   First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million –   Conference call scheduled for today at 8:30 am ET  WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2026") ended December 31, 2025. Revenue by Segment (in millions of USD)  Three Months Ende

    2/9/26 7:00:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026

    WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-445-7795 (Domestic)1-785-424-1699 (International)INOTIV (Co

    2/4/26 6:30:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update

    –  Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million–  Fiscal 2025 revenue increased 4.5% to $513.0 million–  Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million–  Fiscal 2025 operating loss decreased 64.2% to $30.9 million–  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q4 FY 2025") ended September 30, 2025, and twelve mo

    12/3/25 4:05:00 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ACHL
    $BRNS
    $CADL
    $CRIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    12/6/24 4:16:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care